Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Reports Year-End 2014 Financial Results View HTML
Toggle Summary Flexion Therapeutics to Report Year-End 2014 Earnings Results on March 23, 2015 View HTML
Toggle Summary Flexion Therapeutics Announces Changes to Board of Directors View HTML
Toggle Summary Flexion Therapeutics Completes Enrollment in Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006
310 Patients Enrolled in International Multi-Center Trial for the Treatment of Pain Associated With Osteoarthritis (OA) of the Knee
View HTML
Toggle Summary Flexion Therapeutics to Present at RBC Capital Markets Healthcare Conference View HTML
Toggle Summary Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee
Pivotal Trial Designed as Final Clinical Step for FX006 Prior to Flexion Submitting New Drug Application to U.S. Food & Drug Administration
View HTML
Toggle Summary Flexion Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces Pricing of Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces That FDA Has Removed Clinical Hold on FX006 View HTML